Furthermore, we demonstrate that selective NKG2D-ligand upregulation via pharmacologic HDAC inhibition enhances NKG2D-CAR T efficacy against AML, thereby supporting this strategy for combination therapy. This evidence concerns the gene KLRK1 and acute myeloid leukemia.